Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences reported its Q1 FY26 results. On a standalone basis, revenue from operations fell to ₹634.90 million from ₹734.66 million a year ago, a decline of about 13.6%, while standalone profit after tax dipped to ₹78.38 million from ₹84.32 million, and EPS stood at ₹9.21. On a consolidated basis, however, revenue rose modestly to ₹841.05 million (vs ₹822.67 million), but profit after tax more than doubled to ₹172.96 million from ₹74.86 million, with consolidated EPS jumping to ₹20.33 from ₹8.80, helped by a strong contribution from subsidiaries and the joint venture. The Poultry Healthcare segment grew both in revenue and segment profit, while the Animal Healthcare segment saw a sharp drop in revenue and profitability on a standalone basis. The company has also restructured its reportable segments, merging Petcare into Animal Healthcare, with prior period figures restated accordingly. Statutory auditor Chandulal M. Shah & Co. issued an unmodified limited review report on both sets of results.
Mixed picture for shareholders: the standalone business is under pressure with falling revenue and weaker segment performance in Animal Healthcare, but the consolidated story is significantly stronger, driven by subsidiaries and the joint venture, which lifted overall profit sharply. The segment restructuring makes year-on-year comparisons less straightforward, and investors should watch whether the standalone weakness persists in coming quarters.